Check out the updated list of the educational booklets and fact sheets the American Parkinson Disease Association (APDA) offers in English – and Spanish!
Consulte la lista actualizada de folletos educativos y hojas informativas que la Asociación Estadounidense de la Enfermedad de Parkinson (APDA) ofrece en inglés y en español. Desplácese hasta la parte inferior de esta publicación para ver el volante en español y las instrucciones para usar el código QR.
… Full Story>
The Parkinson’s Foundation announced that Stanford is one of four new Centers of Excellence. Kathleen L. Poston, MD, MS, Chief of Movement Disorders for Stanford University said, “Through patient care, education and research, our providers and staff embrace the Foundation’s mission to make life better for people with Parkinson’s disease.” The number of people living with Parkinson’s in the U.S. is expected to rise to 1.2 million by 2030. A central priority of the Foundation is to ensure that all people with PD can obtain the care and support they need to improve their health and quality of life.
… Full Story>
El Centro de información y referencia APDA de Stanford y Stanford Parkinson’s Community Outreach iniciarán un grupo de apoyo para la enfermedad de Parkinson (EP) para la comunidad de habla hispana en agosto de 2023. Estas reuniones virtuales están abiertas a cualquier persona en el norte y centro de California, no solo a las familias de Stanford. Este grupo está disponible a personas con la enfermedad de Parkinson y sus familias.
… Full Story>
The Stanford APDA Information and Referral Center and Stanford Parkinson’s Community Outreach will launch a virtual Parkinson’s disease (PD) support group for the Spanish-speaking community in August 2023. Meetings are open to anyone in the North and Central California, not just Stanford families. This group is available to people with Parkinson’s disease and their families.
… Full Story>
People with Parkinson’s disease or parkinsonism have a much higher risk of hip and other fractures. The TOPAZ (Trial of Parkinson’s and Zoledronic Acid) study will test if zoledronate, an FDA-approved medication for osteoporosis (thinning of the bone), can prevent fractures in people with Parkinson’s disease, whether or not they have osteoporosis. Using zoledronate for this purpose is investigational. Continue reading for a summary of the study and to see if you are eligible to participate. You could receive $100 upon enrollment and $50 per year during the study.
… Full Story>